作者:S.N. Pandeya、P. Yogeeswari、E.A. Sausville、A.B. Mauger、V.L. Narayanan
DOI:10.3797/scipharm.aut-00-34
日期:——
histologies. Leukemia, colon, ovarian and breast cancer cell lines were relatively more sensitive to these compounds than the other cell lines. The 4-carboxy substituted p-nitrobenzylidene phenyl semicarbazone (1c) emerged as the most active compound with average GI50 value (the molar drug concentration required for the 50% growth inhibition) of 28.6µM. This compound showed greater activity than methotrexate
合成了各种4-取代的苯基半卡巴derivatives衍生物,并通过NCI在3细胞系中进行了一次剂量的一级抗癌试验,并在体外进行了评估。三种化合物对乳腺癌MCF7细胞系显示出显着活性,并在体外人类疾病导向肿瘤细胞系筛选小组中进一步评估了其潜在的抗癌活性,该小组由60个人类肿瘤细胞系组成,分布在9个子面板中,代表不同的组织学。与其他细胞系相比,白血病,结肠,卵巢和乳腺癌细胞系对这些化合物的敏感性相对更高。4-羧基取代的对硝基亚苄基苯基半卡巴zone(1c)以GI50平均值(50%生长抑制所需的摩尔药物浓度)为28.6µM成为活性最高的化合物。